Antivirals and Targets to Fight RNA Viruses
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 2079
Special Issue Editors
Interests: structural biology; aptamers; viral RNA genomes; functional RNA
Special Issues, Collections and Topics in MDPI journals
Interests: antiviral nucleic acids; therapeutic RNA; aptamers; RNA inhibitors; structure/function of RNA; RNA viruses
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We would like to invite authors to submit review or original manuscripts focused on the identification of new molecular targets and antiviral drugs to fight against human diseases caused by RNA viruses.
Historically, RNA viruses have co-evolved with humans, producing outbreaks and pandemics that have contributed to understanding their life cycle and molecular biology. From a general point of view, RNA virus cycles share some common stages that include virus entry, translation, replication, assembly and release. These processes have been traditionally chosen to fight viral infections using vaccines, antibodies or chemical inhibitors that interfere with the function of cellular and/or viral proteins. However, these strategies usually fail in their goal due to the emergence of resistant variants. Therefore, the identification of new molecular targets is a main goal in the field.
Recent events regarding the SARS-CoV2 pandemic have also evidenced that RNA viruses can rapidly propagate and emerge as new health threats. For that reason, the development of broad-spectrum compounds that facilitate rapid and universal administration is also a focus of the WHO.
This Special Issue aims to provide an updated overview of current antiviral strategies, their potential limitations and how they can be improved in the near future. Original manuscripts and review articles focused on the identification of new viral and cellular targets that may be useful against infections caused by different RNA viruses, thus facilitating the development of new generic antiviral strategies, are also welcome. Finally, reports on further medical and biotechnological strategies using newly identified viral targets and antiviral compounds will also be considered.
Dr. Cristina Romero-López
Dr. Alfredo Berzal-Herranz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA virus
- antiviral
- drug target
- viral translation
- RNA structure
- viral replication
